спилить дерево на своем участке цена нижний новгород
Главное меню:
Интересное
спилить дерево на своем участке цена нижний новгород, Eli Lilly and Company (LLY) Stock Price & Overview - Stock Analysis, Eli Lilly and Company (LLY) Stock Price, Quote, News & Analysis , Eli Lilly and Company (LLY) Stock Price, News & Analysis, LLY | Eli Lilly & Co. Analyst Estimates & Ratings – WSJ, LLY Stock Price Quote | Morningstar, Eli Lilly and Company (LLY) - Yahoo Finance, Eli Lilly - LLY - Stock Price Today - Zacks.
Watchlist 780.67 +1.39 (0.18%) At close: Jul 3, 2025, 1:00 PM 780.00 -0.67 (-0.09%) After-hours: Jul 3, 2025, 5:00 PM EDT 1D 1 Day 5D 5 Days 1M 1 Month YTD YTD 1Y 1 Year 5Y 5 Years Max Max 0.18% (1D) 700.84B 49.00B Net Income (ttm) 11.11B Shares Out 897.74M EPS (ttm) 12.29 PE Ratio 63.52 Forward PE 31.25 $6.00 (0.77%) Ex-Dividend Date Aug 15, 2025 Volume 1,450,766 Open 780.46 Previous Close 779.28 Day's Range 773.00 - 783.55 52-Week Range 677.09 - 972.53 Beta 0.40 Strong Buy 1,014.65 (+29.97%) Earnings Date Aug 7, 2025 About LLY Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... Industry Sector Founded 1876 Employees Stock Exchange NYSE Ticker Symbol LLY Website Financial Performance In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%. Analyst Summary According to 17 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $1,014.65, which is an increase of 29.97% from the latest price. Price Target $1,014.65 (29.97% upside) Analyst Consensus: Strong Buy News All Videos PressPress Releases Conversation Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns. Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with Lilly and Novo. 2 days ago - Barrons Top 50 High-Quality Dividend Stocks For July 2025 I track 50 high-quality dividend growth stocks to identify opportune investments, updating valuation ratings daily to focus on attractive opportunities. In this turbulent year, my investable universe ... Other symbols: 4 days ago - Seeking Alpha Top 15 High-Growth Dividend Stocks For July 2025 My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, tho... Other symbols: 4 days ago - Seeking Alpha CVS drops Lilly's Zepbound CNBC's Angelica Peebles reports on news regarding CVS. Other symbols: 4 days ago - CNBC Television Eli Lilly seen as the stronger bet amid escalating competition with Novo in India The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India, one of the fastest-growing pharmaceutical frontiers. As rising obesity an... 10 days ago - Invezz Lilly to launch Mounjaro pen in India to compete with Novo's Wegovy Eli Lilly said on Thursday India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk... Other symbols: 10 days ago - Reuters Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate Eli Lilly is positioned for a 30-50% return in the next 12 months based on a nexus of value and growth. While others hesitate on greatness, I buy at the prices everyone else wishes they did. Risks are... 10 days ago - Seeking Alpha Weight loss and diabetes jabs linked to potentially fatal side effect Weight loss and diabetes jabs taken by more than a million people in the UK have been linked to a potential serious side effect, with some deaths, according to data from the UK medicines regulator. Other symbols: 10 days ago - Skynews Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round. 10 days ago - CNBC Eli Lilly: It Is A Bet On Human Longevity Eli Lilly's recent stock dip creates a compelling buying opportunity, with its valuation multiples falling to 2022 levels, despite explosive growth prospects and a deep, innovative product pipeline. D... 12 days ago - Seeking Alpha Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space. Other symbols: 12 days ago - CNBC Television Lilly declares third-quarter 2025 dividend INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common ... 13 days ago - PRNewsWire Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript Eli Lilly and Company (NYSE:LLY) Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June 22, 2025 7:30 PM ET Company Participants Jeffrey... 13 days ago - Seeking Alpha Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora f... 13 days ago - PRNewsWire Lilly expects orforglipron obesity results in third quarter Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the drug... 15 days ago - Reuters Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes In ACHIEVE-1, orforglipron a... 15 days ago - PRNewsWire Final Trade: LLY, SHEL, USO, WMT The final trades of the day with the Fast Money traders. Other symbols: 15 days ago - CNBC Television Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD ... Other symbols: 15 days ago - Reuters 3 'Underdog Stocks' For The Rest Of 2025 With the S&P 500 Index meandering along at a 1.69% year-to-date return, you can't fault investors looking for some juice out of their portfolios at the mid-point of 2025. Other symbols: 15 days ago - Benzinga This AI Trader Bought Meta Stock and Dumped Eli Lilly Traders now can have an AI stockpicker make those tough investment decisions Other symbols: 16 days ago - Barrons Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country. 16 days ago - Reuters VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Verve... Other symbols: 17 days ago - Business Wire Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug Kisunla, blocking access for patients seeking treatment under the country'... 17 days ago - Reuters Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study Scholar Rock SRRK revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced ... Other symbols: 18 days ago - Benzinga Beyond Obesity: Eli Lilly's Genetic Medicine Bet On Verve Therapeutics Eli Lilly's $1.3 billion acquisition of Verve Therapeutics represents a strategic move into cardiovascular genetic medicine. The pharmaceutical behemoth paid a substantial premium of approximately 113... 18 days ago - Forbes Load More News Sections Stocks IPOs ETFs Blog Services Stock Analysis Pro Free Newsletter Get Support Install The App Website Login Create Account Changelog Sitemap Advertise FAQ Company About Contact Us Terms of Use Privacy Policy Data Disclaimer Affiliate Program Market Newsletter Daily market news in bullet point format. Subscribe Site Theme Light Dark © 2025 StockAnalysis.com. All rights reserved. , A detailed overview of Eli Lilly and Company (LLY) stock, including real-time price, chart, key statistics, news, and more., A high-level overview of Eli Lilly and Company (LLY) stock. View (LLY) real-time stock price, chart, news, analysis, analyst reviews and more..
Should You Buy or Sell Eli Lilly and Company Stock? Get The Latest LLY Stock Analysis, Price Target, Dividend Info, Headlines, and Short Interest at MarketBeat., Eli Lilly & Co. analyst ratings, historical stock prices, earnings estimates & actuals. LLY updated stock price target summary., See the latest Eli Lilly and Co stock price (LLY:XNYS), related news, valuation, dividends and more to help you make your investing decisions., See Eli Lilly and Company (LLY) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades., Get the latest Eli Lilly and Company LLY detailed stock quotes, stock data, Real-Time ECN, charts, stats and more., Eli Lilly and Company (LLY) stock analysis and DCF fair value estimates. Review key financial metrics like market cap of $, P/E ratio of 63.41, and dividend yield of 0.77%..